Literature DB >> 16690971

Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.

Karen Stephens1, Molly Weaver, Kathleen A Leppig, Kyoko Maruyama, Peter D Emanuel, Michelle M Le Beau, Kevin M Shannon.   

Abstract

To identify the mechanism of loss of heterozygosity (LOH) and potential modifier gene(s), we investigated the molecular basis of somatic NF1 inactivation in myeloid malignancies from 10 children with neurofibromatosis type 1. Loci across a minimal 50-Mb region of primarily the long arm of chromosome 17 showed LOH in 8 cases, whereas a less than 9-Mb region of loci flanking NF1 had LOH in the remaining 2 cases. Two complementary techniques, quantitative polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH), were used to determine whether the copy number at loci that showed LOH was 1 or 2 (ie, deleted or isodisomic). The 2 cases with LOH limited to less than 9 Mb were intrachromosomal deletions. Among the 8 leukemias with 50-Mb LOH segments, 4 had partial uniparental isodisomy and 4 had interstitial uniparental isodisomy. These isodisomic cases showed clustering of the centromeric and telomeric LOH breakpoints. This suggests that the cases with interstitial uniparental isodisomy arose in a leukemia-initiating cell by double-homologous recombination events at intervals of preferred mitotic recombination. Homozygous inactivation of NF1 favored outgrowth of the leukemia-initiating cell. Our studies demonstrate that LOH analyses of loci distributed along the chromosomal length along with copy-number analysis can reveal novel mechanisms of LOH that may potentially identify regions harboring "cryptic" tumor suppressor or modifier genes whose inactivation contributes to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16690971      PMCID: PMC1895516          DOI: 10.1182/blood-2005-11-011486

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 3.  Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays.

Authors:  Xiaofeng Zhou; Nagesh P Rao; Steven W Cole; Samuel C Mok; Zugen Chen; David T Wong
Journal:  Cancer Genet Cytogenet       Date:  2005-05

4.  Myeloid malignancies induced by alkylating agents in Nf1 mice.

Authors:  N Mahgoub; B R Taylor; M M Le Beau; M Gratiot; K M Carlson; S K Atwater; T Jacks; K M Shannon
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

7.  Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias.

Authors:  Manoj Raghavan; Debra M Lillington; Spyros Skoulakis; Silvana Debernardi; Tracy Chaplin; Nicola J Foot; T Andrew Lister; Bryan D Young
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

8.  Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array.

Authors:  Xiaofeng Zhou; Samuel C Mok; Zugen Chen; Yang Li; David T W Wong
Journal:  Hum Genet       Date:  2004-09       Impact factor: 4.132

9.  Whole genome DNA copy number changes identified by high density oligonucleotide arrays.

Authors:  Jing Huang; Wen Wei; Jane Zhang; Guoying Liu; Graham R Bignell; Michael R Stratton; P Andrew Futreal; Richard Wooster; Keith W Jones; Michael H Shapero
Journal:  Hum Genomics       Date:  2004-05       Impact factor: 4.639

10.  A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation.

Authors:  Giuseppe Saglio; Clelia T Storlazzi; Emilia Giugliano; Cecilia Surace; Luisa Anelli; Giovanna Rege-Cambrin; Antonella Zagaria; Antonio Jimenez Velasco; Anabel Heiniger; Patrizia Scaravaglio; Antoni Torres Gomez; José Roman Gomez; Nicoletta Archidiacono; Sandro Banfi; Mariano Rocchi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-11       Impact factor: 11.205

View more
  20 in total

Review 1.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

2.  Cancer: More than kin and less than kind.

Authors:  Kevin Shannon; Mignon Loh
Journal:  Nature       Date:  2009-08-13       Impact factor: 49.962

Review 3.  Central nervous system lymphoma occurring in a patient with neurofibromatosis type 1 (von Recklinghausen disease).

Authors:  Marica Eoli; Donata Bianchessi; Anna Luisa Di Stefano; Elena Prodi; Elena Anghileri; Gaetano Finocchiaro
Journal:  Neurol Sci       Date:  2012-12       Impact factor: 3.307

Review 4.  Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.

Authors:  Sebastian Laycock-van Spyk; Nick Thomas; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2011-10       Impact factor: 4.639

Review 5.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

6.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

7.  Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.

Authors:  David Caudell; David P Harper; Rachel L Novak; Rachel M Pierce; Christopher Slape; Linda Wolff; Peter D Aplan
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

8.  Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.

Authors:  Doris Steinemann; Larissa Arning; Inka Praulich; Manfred Stuhrmann; Henrik Hasle; Jan Stary; Brigitte Schlegelberger; Charlotte M Niemeyer; Christian Flotho
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia.

Authors:  Barbara-Ann Guinn; Azim Mohamedali; Ken I Mills; Barbara Czepulkowski; Michael Schmitt; Jochen Greiner
Journal:  Biomark Insights       Date:  2007-02-14

Review 10.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.